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Summary
The striatum receives rich dopaminergic and more
moderate serotonergic innervation. After vesicular re-
lease, dopamine and serotonin (5-hydroxytryptamine,
5-HT) signaling is controlled by transporter-mediated
reuptake. Dopamine is taken up by dopamine trans-
porters (DATs), which are expressed at the highest
density in the striatum. Although DATs also display a
low affinity for 5-HT, that neurotransmitter is normally
efficiently taken up by the 5-HT transporters. We
found that when extracellular 5-HT is elevated by ex-
ogenous application or by using antidepressants
(e.g., fluoxetine) to inhibit the 5-HT transporters, the
extremely dense striatal DATs uptake 5-HT into dopa-
mine terminals. Immunohistochemical results and
measurements using fast cyclic voltammetry showed
that elevated 5-HT is taken up by DATs into striatal
dopamine terminals that subsequently release 5-HT
and dopamine together. These results suggest that
antidepressants that block serotonin transporters or
other factors that elevate extracellular 5-HT alter the
temporal and spatial relationship between dopamine
and 5-HT signaling in the striatum.
Introduction
The striatum is a large subcortical structure in the
mammalian brain that is involved in motor coordination,
cognitive functions, and complex processes associ-
ated with adaptive behaviors (Lang and Lozano, 1998;
Berke and Hyman, 2000; McClure et al., 2003; Schultz
et al., 2003; Zhou et al., 2003). A distinguishing feature
of the striatum is its extremely dense dopamine (DA)
innervation (Björklund and Lindvall, 1984). The dense
DA axon terminals provide the strongest expression of
DA transporters (DATs) in the brain (Ciliax et al., 1995;
Coulter et al., 1996; Sesack et al., 1998). The striatum
also receives more modest 5-HT innervation, and those
fibers express the 5-HT transporters (Steinbusch, 1981;
Pickel and Chan, 1999). Ultrastructurally, 5-HT ter-
minals are in close proximity to DA terminals (Van Bock-
staele and Pickel, 1993), providing an anatomical basis*Correspondence: jdani@bcm.tmc.edu
3 Present address: Department of Pharmacology, University of Ten-
nessee, Memphis, Tennessee 38163.for the two systems to interact with each other. Further-
more, the extracellular 5-HT concentration is likely to
be high near release sites because 5-HT is highly con-
centrated within releasable vesicles (Bruns et al., 2000)
and there is no extracellular enzyme to degrade 5-HT.
DATs have been shown to bind 5-HT with a low affinity,
which is estimated to be about 1/15 of the affinity for
DA (Giros et al., 1991; Pristupa et al., 1994; Eshleman
et al., 1999). Evidence also suggests that depression
and the mechanistic action of antidepressants are influ-
enced by DA and by DA and 5-HT interactions in the
striatum (Laasonen-Balk et al., 1999; D’Aquila et al.
2000; Meyer et al. 2001; Zangen et al. 2001; Willner
2002). Encouraged by that information, we examined
the influence of DATs on 5-HT signaling in the striatum and
found that under some conditions DATs uptake 5-HT into
DA terminals. Subsequently, 5-HT and DA are released
together, thereby altering the relationship between DA
and 5-HT signaling and inducing some DA and 5-HT
cosignaling.
Results
Elevated 5-HT Enters Dopamine Terminals
To determine whether 5-HT can accumulate in DA ter-
minals, we used double immunostaining with antibod-
ies against tyrosine hydroxylase (TH) and 5-HT to visu-
alize their colocalization in striatal axon terminals
(Figure 1). TH is the key enzyme for DA and norepineph-
rine synthesis. Norepinephrine (NE) axon terminals
comprise a small minority of the TH-positive terminals
in the striatum. Therefore, the TH labeling in the stria-
tum can be assigned almost exclusively to DA terminals
(Feuerstein et al., 1986; Sesack, 2002).
Under drug-free control conditions, the modest num-
ber of 5-HT terminals (Figure 1A1, red) and the dense
DA terminals (Figure 1A2, green) were often next to
each other, but did not generally overlap (Figure 1A3).
This result is consistent with previous studies (Descarries
and Mechawar, 2000). We increased the external 5-HT
concentration by directly adding exogenous 5-HT to
the bathing solution. After incubating a striatal slice in
exogenous 5-HT (1–2 M) for 2 hr, a different result
emerged. There was a dramatic increase in the number
of 5-HT-positive terminals (Figure 1B1, red), but the
number of TH-positive DA terminals remained relatively
constant (Figure 1B2, green). Superimposition of the
images and counting of individual terminals indicated
that the majority (w80%) of the 5-HT-positive terminals
and the TH-positive terminals overlapped with each other
(Figure 1B3, yellow). The result suggests that 5-HT has
entered into DA terminals and that elevating external
5-HT caused DA terminals to acquire a dual neuro-
chemical identity, containing both 5-HT and DA. Be-
cause DA terminals do not express 5-HT transporters
(Pickel and Chan, 1999), DATs appeared to be responsi-
ble for uptaking 5-HT into the DA terminals.
To examine the role of the DATs, we specifically inhib-































(Figure 1. Anatomical Visualization of 5-HT Accumulation in Striatal
iDA Terminals
c(A) Under control conditions, 5-HT axon terminals as detected by
anti-5-HT antibody are relatively sparse (red, [A1]), and DA ter- F
minals as detected by anti-tyrosine hydroxylase (TH) antibody are 5
dense (green, [A2]). The DA and 5-HT terminals generally do not s
overlap (absence of yellow, [A3]). (
(B) Incubation with 2 M 5-HT for 2 hr increases 5-HT-positive ter-
cminals (red, [B1]), and DA terminals are relatively unchanged
b(green, [B2]). Most of the 5-HT-positive terminals coincide with DA
terminals (yellow, [B3]), suggesting that DA terminals in this case w
also contain 5-HT. t
(C) Pretreatment with the DAT inhibitor GBR12909 (1 M) blocks D
the effect of 2 M 5-HT. 5-HT terminals remain sparse (red, [C1]), a
DA terminals are dense and unchanged (green, [C2]), and the 5-HT-
positive terminals rarely coincide with TH-positive terminals (yel-
Glow, [C3]). Scale bar, 10 m.
(D) The HPLC-measured striatal 5-HT content (red bars, left scale, G
in nmole/g wet tissue) is low under control conditions, increases 3
after bathing the slice in 2 M 5-HT, and is near the control value f
when DATs are inhibited by 1 M GBR12909 before the 5-HT treat- D
ment (GRB + 5-HT). In contrast, the DA content (green bars, right
cscale, in nmole/g wet tissue) is high under control conditions, de-
wcreases after bathing the slice in 5-HT, and is near the control value
when DATs are inhibited by GBR12909 before the 5-HT treatment (
(GRB+5-HT). Standard error bars are shown. D
w
g
5al., 1994) before and while applying 5-HT (2 M) to the
pstriatal slice preparation. With the DATs inhibited, the
number of 5-HT-positive terminals was not increased
(Figure 1C1, red). The DA terminals remained dense I
U(Figure 1C2, green), and there was very little overlap
between the 5-HT and DA terminals (Figure 1C3). These T
results suggest that there is a DAT-mediated uptake of-HT into striatal DA terminals when extracellular 5-HT
s elevated.
To observe the influence of the DATs alone, fluoxetine
nd nisoxetine (each at 1 M) were present in all of
hese experiments to block entry of exogenous 5-HT
nto intrinsic 5-HT and NE axons, respectively. However,
he absence of 5-HT and NE transporter inhibitors did
ot cause an obvious difference in 5-HT fluorescence
n DA terminals because the high concentration of ex-
genous 5-HT likely overwhelmed the 5-HT transpor-
ers in these experiments. Incubation with 0.1 and 0.5
M 5-HT or shorter incubation times of 0.5–1 hr also
ncreased the number of 5-HT-positive terminals, but to
lesser extent than 1–2 M 5-HT incubated for 2 hr
data not shown).
uantification of the Accumulation of Exogenous
-HT into DA Terminals
o quantify the anatomically detected neurochemical
hanges, we employed high-performance liquid chro-
atography (HPLC) because of its precision and speci-
icity. We determined the content of 5-HT and DA from
triatal slices under the same experimental conditions
sed to obtain the images of Figures 1A–1C. Under
ontrol conditions (Figure 1D, Control), the 5-HT con-
ent in the dorsolateral striatum was 3.5 ± 0.2 nmoles/
wet tissue, and the DA content was 105.4 ± 5.5
moles/g wet tissue (n = 20 samples from five mice).
After incubating striatal slices in 2 M 5-HT for 2 hr
nd washing away the extracellular excess, the striatal
-HT content increased 11-fold and the DA content de-
reased by 60% ± 4% (n = 16 samples from four mice)
Figure 1D, 5-HT). These results are consistent with the
mages of Figures 1A and 1B, and together they indi-
ate that 5-HT was being taken into the DA terminals.
urthermore, striatal DA content was reduced by the
-HT incubation, whereas the DA turnover rate, as mea-
ured by the ratio of 3,4-dihydroxyphenylacetic acid
DOPAC) to DA, increased from 0.08 ± 0.01 (n = 6) under
ontrol conditions to 0.14 ± 0.01 (n = 6) after 2 hr incu-
ation in 2 M 5-HT. These results suggest that 5-HT
as displacing DA from DA vesicles in the striatal DA
erminals such that relatively more DA was outside of
A vesicles and exposed to breakdown by mono-
mine oxidases.
To test the role of the DATs, they were inhibited by
BR12909 (1 M) before adding 2 M 5-HT (Figure 1D,
BR+5-HT). In that case, the 5-HT content was only
0% ± 4% higher than the control (n = 16 samples from
our mice), as compared to the 1100% increase when
ATs were not inhibited by GBR12909. This small in-
rease in 5-HT content in the presence of GBR12909
as likely due to nonspecific uptake or binding
Krueger, 1990). Because 5-HT was not taken up into
A terminals under these conditions, the DA content
as statistically unchanged from the control. Taken to-
ether, the results of Figure 1 suggest that elevated
-HT is taken up into DA terminals and that 5-HT dis-
laces some of the DA content within the terminals.
dentifiable DA and 5-HT Signals Measured
sing Voltammetry
he anatomical and HPLC data of Figure 1 suggestedthat 5-HT can colocalize with DA in DA terminals. We
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subsequently released together. To monitor the real-
time, physiological release of DA and 5-HT in striatal
slices, we used fast-scan cyclic voltammetry to mea-
sure the identifiable oxidation-reduction profiles (or vol-
tammograms) of DA and 5-HT (Kawagoe et al., 1993;
Iravani and Kruk, 1997; Bunin and Wightman, 1998;
Zhou et al., 2001). Measured with a carbon-fiber micro-
electrode, the distinct voltammograms of DA and 5-HT
are particularly different near their reduction minima,
which are near −250 mV (−220 to −280 mV) for DA and
near −30 mV (0 to −50 mV) for 5-HT.
To test the sensitivity of this approach, we conducted
control experiments in a simple bath solution without
any neural tissue. In the electrolyte solution, pure DA
was applied to the carbon-fiber electrode (solid bar,
Figure 2A). The full voltammogram at the peak of the
DA response (t1) is shown in Figure 2B, and the ex-
panded reduction arm is shown in Figure 2C. The vol-
tammogram shows the DA reduction minimum nearFigure 2. Fast-Scan Cyclic Voltammetry Identifies DA and 5-HT Be-
cause They Have Different Potentials for Their Reduction Minima
In simple electrolyte solutions, this control experiment shows that
applications of DA or 5-HT onto a carbon-fiber microelectrode pro-
duce identifiable signals. (A) The time course is shown for the car-
bon-fiber microelectrode response to an application of pure DA (2
M, 1 s). (B) The complete voltammogram is shown at time t1,
which is the peak of the response to the DA application. The oxida-
tion-reduction profile is plotted as current versus the voltage. The
reduction minimum is near −230 mV (green line). (C) The normalized
and expanded DA reduction arm shows the DA reduction minimum
more clearly (green line, near −230 mV) and shows the separation
from the 5-HT reduction minimum (red line). (D) The time course is
shown for the response to an application of pure 5-HT (1 M, 1 s)
onto the same carbon-fiber microelectrode. (E) The complete volt-
ammogram is shown at time t1, which is the peak of the response.
The reduction peak is near −30 mV (red line). (F) The normalized
and expanded 5-HT reduction arm shows the 5-HT reduction mini-
mum more clearly (red line, near −30 mV) and shows the separation
from the DA reduction minimum (green line). (G) The time course is
shown for the response to a mixture of DA and 5-HT (1 and 0.5 M,
1 s) onto the same carbon-fiber microelectrode. (H) The complete
voltammogram is shown at time t1, which is the peak of the re-
sponse. The reduction minimum for the mixture is spread out
through the range from −30 mV (red line for 5-HT) to −230 mV
(green line for DA). (I) The normalized and expanded mixed DA/
5-HT reduction arm shows the broad reduction peak ranging from
−30 mV (red line) to −230 mV (green line).−230 mV, as indicated by the vertical green line. Thereis no significant signal for 5-HT at the reduction mini-
mum of −30 mV (red line). Four seconds after the peak
of the response (t2 in Figure 2A) there was no DA signal
because DA had cleared from the carbon-fiber surface.
When pure 5-HT was applied in the same manner to
the same carbon-fiber electrode (solid bar, Figure 2D),
a longer-lasting signal resulted because 5-HT cleared
from the carbon-fiber surface more slowly. The full vol-
tammogram at the peak of the 5-HT response (t1) is
shown in Figure 2E, and the expanded reduction arm is
shown in Figure 2F. The voltammograms show the
5-HT reduction minimum near −30 mV, as indicated by
the vertical red line. Four seconds after the peak of the
5-HT response (t2 in Figure 2D) there was still a small
observable signal above the baseline because 5-HT
clears from the carbon-fiber surface more slowly. Fi-
nally, when a mixture of DA and 5-HT was applied to
the carbon-fiber microelectrode (solid bar, Figure 2G),
the voltammogram displayed a broad reduction mini-
mum that extended between the minimum for pure DA
(green line) and the minimum for pure 5-HT (red line)
(Figures 2H and 2I). At time t2 (Figure 2G), only the
5-HT signal was detected. An important distinguishing
feature is that the clearance of 5-HT from the carbon-
fiber microelectrode is much slower than the clearance
of DA, such that the 5-HT signal can be recorded at the
microelectrode after the DA signal has declined into the
baseline. These properties were used later to identify
exocytotic release of DA and 5-HT in striatal slices.
Real-Time Monitoring of 5-HT and DA
Corelease in the Striatum
A bipolar simulating electrode was placed into dorso-
lateral striatal brain slices about 150 m from the car-
bon-fiber microelectrode, and neurotransmitter release
was electrically evoked every 2.5 min at 60% of the
maximal response. Under control conditions, both
spontaneous and electrically evoked release decayed
rapidly, taking 1.1 ± 0.1 s (n = 12 recordings) to decline
from 90% to 10% (Figure 3A). At the peak of the re-
sponse (t1), a large DA signal was detected at the car-
bon fiber, as identified by its characteristic voltammo-
gram and quantified in Figure 3B. Four seconds after
the maximum (t2), the signal had declined to <10% of
the peak value (Figure 3B). Along the baseline, small
spontaneous events can be observed (Figure 3A), and
analysis of the voltammograms showed these to be
pure DA release (data not shown). A 5-HT component
is not detected under normal conditions because the
5-HT content in control slices is very low and the physi-
ologically released 5-HT is below the level of detection.
To examine the consequences of elevated external
5-HT, we bathed the striatal slices in 2 M 5-HT and
digitally subtracted the background 5-HT signal from
our recordings. The presence of 5-HT greatly enhanced
and prolonged both spontaneous and electrically
evoked voltammetric signals (Figure 3C). The time for
the evoked signal to decay (from 90% to 10%) in-
creased 16 ± 1-fold (n = 12 recordings in 12 slices) over
the control condition. At the peak of the response (t1),
the signal was a mixture of DA and 5-HT showing an
extended reduction peak (from −30 to −250) in the vol-
tammogram (Figure 3C). The DA concentration at the









Figure 3. Fast-Scan Cyclic Voltammetry Reveals 5-HT and DA
o
Corelease in the Striatum
t
(A) A control trace showing small spontaneous voltammetric events (
and two large electrically stimulated responses. The scale bars are s
1 M DA and 30 s. Time t1 indicates the peak of the signal. At time m
t2, 4 s after the peak, the signal is small but still detectable. The r
two voltammograms (below) from t1 and t2 are typical DA voltam- n
mograms with the oxidation peak near 500 mV and the reduction i
peak near −230 mV (dotted vertical lines). The y axis of the voltam- p
mograms varies and is labeled for comparison in nA. (B) Under t
control conditions at the maximum of the evoked release (t1 in a
panel [A]), the voltammogram analysis indicated a pure DA signal
with no detectable 5-HT signal. The DA signal decayed rapidly,
1such that there was a barely detectable DA signal 4 s after the peak
(t2 in panel [A]). (C) In the presence of 2 M 5-HT after subtracting o
off the 5-HT background, both the spontaneous and evoked events e
are larger and longer lasting than in the control case. The voltam- p
mogram from t1 is a mixed DA/5-HT voltammogram with a broad
4reduction peak from −230 mV (dotted vertical line) to −30 mV (ar-
erow), whereas the voltammogram from t2 is a predominantly 5-HT
lvoltammogram with a reduction peak at −30 mV (arrow). (D) Voltam-
mogram analysis indicates that, at t1, the signal is a mixture of DA
and 5-HT. The peak DA concentration (t1 in panel [C]) was reduced s
byw50%, whereas the 5-HT concentration was increased from an o
undetectable level to w0.5 M. Note that the ordinate scale has
dchanged from that in panel [B]. At time t2, the 5-HT concentration
tdecayed to w0.3 M and the DA signal was no longer detectable.
oStandard error bars are shown.
(
w
nbut the 5-HT concentration increased from essentially
0 in the control to 0.5 ± 0.1 M (n = 8 slices). Four t
Tseconds after the maximum (t2), only a 5-HT signal was
detected (Figure 3D). This finding is consistent with the l
rmore rapid reuptake of DA by the DATs and slower
clearance of 5-HT from the carbon fiber when com- o
Ipared to DA (see Figure 2).
m
cSpontaneous Vesicular 5-HT and DA Corelease
in the Striatum t
Spontaneous vesicular neurotransmitter release is an
important part of neuronal activity. Thus, we examined w
cwhether DA and 5-HT were released together sponta-
neously in the absence of electrical stimulation. Under (
fcontrol conditions, spontaneous DA release was ob-
served in the baseline of the recordings (Figures 3A and r
c4A). These spontaneous events were fast, with rise
times of 0.1 ± 0.01 s (10% to 90%) and decay times of digure 4. Incubation with 5-HT Induces Spontaneous, Vesicular
-HT and DA Corelease from DA Terminals in the Striatum
A) A segment of a recording of fast spontaneous events is shown
nder control conditions. The short duration of the spontaneous
vent is due to the efficient reuptake of DA by DATs. To the right,
he voltammograms are shown at the maximum (t1) and at the de-
ay foot (t2) of a spontaneous event. Both show the typical DA
xidation peak near 500 mV and reduction peak near −230 mV (dot-
ed vertical lines). All the voltammograms are on the same scale.
B) A segment of a recording of slower spontaneous events is
hown after incubation with 2 M 5-HT. The voltammogram at the
aximum (t1) is a mixed DA and 5-HT voltammogram with a broad
eduction peak ranging from near −230 mV (vertical dotted line) to
ear −30 mV (arrow). The voltammogram as the signal decays (t2)
s predominately 5-HT with its voltammogram showing a reduction
eak near −30 mV (arrow). The prolonged decay is likely due to
he inefficient uptake of 5-HT by DATs. All spontaneous events are
bolished by 0.5 M TTX or 0 mM Ca2+..2 ± 0.1 s (90% to 10%). The voltammogram shapes
f the spontaneous events were identical to those of
voked DA events, having oxidation and reduction
eaks at the same potentials as DA standards (Figure
A). After incubation with 2 M 5-HT, the spontaneous
vents were prolonged (Figure 4B), similar to the pro-
ongation of electrically stimulated events (Figures 3C).
To determine the chemical nature of these prolonged
pontaneous events, we examined the voltammograms
f 40 randomly chosen spontaneous events from eight
ifferent slices (five events from each slice). In all cases,
he rising phase and the maximum of these spontane-
us events were mixed signals of both DA and 5-HT
t1, Figure 4B). The falling phase of the events, however,
as predominantly 5-HT with only a small DA compo-
ent. Four seconds after the maximum response, only
he 5-HT component was detected (t2, Figure 4B).
hese results indicate that DA and 5-HT were being re-
eased together spontaneously and that there is more
apid reuptake of DA by DATs and more rapid clearance
f DA than 5-HT from the carbon-fiber microelectrode.
f 5-HT and DA were being released from different ter-
inals, then some spontaneous events would have
ontained only DA and some others would have con-
ained only 5-HT.
All the spontaneous and electrically evoked events
ere reversibly blocked by 0.5 M tetrodotoxin, a Na+
hannel blocker (n = 3), or by 0 mM extracellular Ca2+
n = 2), indicating that these spontaneous signals arise
rom action potential-dependent vesicular or quantal
elease from DA terminals. Incubation with lower con-
entrations of 5-HT (0.05, 0.1, 0.5, and 1 M) also in-
uced 5-HT/DA corelease, but the 5-HT component
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69was smaller than that seen with 2 M 5-HT (data not
shown).
5-HT Corelease with DA Requires Dopamine
Transporter Activity
The evidence to this point indicates that elevated extra-
cellular 5-HT induces 5-HT accumulation and, subse-
quently, corelease of DA and 5-HT from DA terminals.
DA terminals express DATs, but they do not express
5-HT transporters (Pickel and Chan, 1999). Therefore,
we examined whether the DATs were required for this
uptake of extracellular 5-HT. We inhibited DATs before
elevating 5-HT in the bathing solution. Striatal slices
were first treated for 1 hr with the DAT inhibitor
GBR12909 (0.1 or 1 M), which caused the expected
prolongation of both spontaneous and evoked DA re-
lease (Figure 5A). Under those conditions, application
of 5-HT (2 M) did not enhance or prolong either the
spontaneous or the electrically evoked signals. On the
contrary, with the DATs inhibited, 5-HT decreased DA
release by 22% ± 2% (n = 5) (Figure 5B), which was
likely mediated by events initiated by 5-HT receptor ac-
tivity (Barnes and Sharp, 1999). In addition, analysis of
the voltammograms showed clearly that the evoked
and spontaneous release contained only a DA compo-
nent, and no 5-HT component was detected through-
out the time course of the signal (inset of Figure 5B).
These results further confirm that DAT-mediated uptake
of 5-HT into DA terminals is required for the vesicular
release of 5-HT with DA (see Figures 3 and 4).
In Vivo Chronic Antidepressant Treatment Induces
DAT-Dependent 5-HT Accumulation in the Striatum
Antidepressants such as fluoxetine are selective sero-
tonin reuptake inhibitors (SSRIs) that prolong and ele-
vate the extracellular 5-HT signals within hours after
drug administration (Knobelman et al., 2000; Smith etFigure 5. Dopamine Transporter Activity Is Required for the 5-HT-
Induced Corelease of 5-HT and DA
(A) A trace is shown with small spontaneous and two large electri-
cally evoked voltammetric events obtained in the presence of the
DAT inhibitor GBR12909. DAT inhibition prolongs the decay of both
evoked and spontaneous DA signals. The voltammograms used to
construct the trace are all typical of DA with oxidation peaks near
500 mV and reduction peaks near −230 mV (vertical dotted line).
An example voltammogram (inset) is shown from the time indicated
by the arrow on the falling phase.
(B) With the DATs inhibited by 1 M GBR12909, bath application of
2 M 5-HT decreased the amplitude of the evoked and spontane-
ous DA signals. The voltammograms (inset) from the falling phase
of the evoked event is indicative of pure DA without any 5-HT com-
ponent because the inhibited DATs could not uptake 5-HT.
(C) After a prolonged wash out of the 5-HT, the electrically evoked
DA signal returned to the initial amplitude. Sulpiride (1 M) was
present during the entire experiment to prevent D2 receptor-medi-
ated autoinhibition of DA release.al., 2000; Wong et al., 1995). Therefore, we examined
whether this antidepressant-induced elevation of extra-
cellular 5-HT leads to uptake of 5-HT by DATs. This
question is much more difficult because of the low level
of endogenous 5-HT in the striatum (see Figure 1D).
Pilot experiments indicated that immunostaining was
not sensitive enough to resolve this question convinc-
ingly, but HPLC has much greater sensitivity.
As a control experiment, we daily injected mice with
GBR12909 (5 mg/kg) alone. The treatment did not affect
striatal 5-HT content, indicating that GBR12909 was
not directly blocking 5-HT transporters and DATs are
not normally important for 5-HT uptake. Then, we in-
jected mice with saline, fluoxetine, or fluoxetine and
GBR12909 and assayed striatal 5-HT content using
HPLC. Treatment with fluoxetine alone (10 mg/kg body
weight) modestly and gradually reduced striatal 5-HT
content (Figure 6A, filled circles). Taken together, the
5-HT contents on day 6 to day 18 were significantly
lower after fluoxetine treatment as compared to treat-
ment with saline or GBR12909 alone (n = 15–30 sam-
ples from three to six mice, p = 0.02). This small de-
crease in 5-HT content likely arose from 5-HT lost from
the tissue because fluoxetine prevented proper 5-HT
reuptake into serotonergic terminals (Torres et al.,
2003).
To examine the role of the DATs during SSRI treat-
ment, we daily injected another set of mice with the
combination of fluoxetine (10 mg/kg) and GBR12909
(5 mg/kg), a specific DAT inhibitor (Pristupa et al., 1994).
With both the 5-HT transporters and the DATs inhibited
(Figure 6, open circles), the 5-HT content of striatal tis-
sue fell by 17% on average after 10 days (n = 20 sam-
ples from five mice, p = 0.01). Taken together, the 5-HT
content from day 6 to day 18 was significantly lower
after combined treatment as compared to treatment
with fluoxetine alone (n = 15–25 samples from three to
five mice, p = 0.05). This result suggests that there wasFigure 6. Chronic 5-HT Transporter Blockade by the SSRI Fluoxe-
tine Induces DAT-Dependent Accumulation of Striatal 5-HT
Mice were given daily injections of 10 mg fluoxetine (Fluox) per kg
body weight (filled circles) or 5 mg/kg GBR12909 with 10 mg/kg
fluoxetine (open circles). Daily injections of saline or GBR12909
alone did not alter striatal 5-HT content (shown as a dashed base-
line for clarity in nmole/g wet tissue). Inhibiting 5-HT transporters
with fluoxetine (filled circles) slightly lowered 5-HT content. Inhibit-
ing both 5-HT transporters and DATs with GBR12909 (open circles)
reduced 5-HT content more, indicating that a portion of striatal
5-HT content during chronic fluoxetine treatment was being taken
up by DATs (gray area).
Neuron
70greater loss of 5-HT content when DATs were inhibited,
preventing 5-HT from being taken into the DA terminals.
Consistent with that interpretation, the area shaded in
gray (Figure 6) indicates the content of 5-HT that was
taken up by DATs when the 5-HT transporters were in-
hibited. In agreement with the previous results, these in
vivo data indicate that during fluoxetine treatment 5-HT
is taken up into DA terminals.
Endogenous 5-HT Release from DA Terminals
after Fluoxetine Treatment
The HPLC experiments (Figure 6) suggest that 5-HT is
taken into DA terminals in vivo after fluoxetine treat-
ment. That hypothesis implies that we could detect the
corelease of 5-HT and DA with voltammetry after the
in vivo treatment with fluoxetine. The problem is that
voltammetry does not have the high sensitivity ob-
tained with HPLC. Despite the shortcomings, we cut
slices from mice chronically injected with fluoxetine
and examined the voltammograms. Under certain ex-
perimental conditions (see Experimental Procedures),
we could detect the corelease of 5-HT and DA. To
quantify the changes in the 5-HT signal induced by the
different in vivo treatments and to normalize the sensi-
F
tivity of the carbon-fiber electrodes, we calculated the T
ratio of the reduction current at −30 mV (5-HT reduction
(
peak) over the total oxidation current peak (R/O ratio, f
Figure 7A). After 21 days of fluoxetine treatment with d
lthe last injection coming 2 hr before cutting dorsal stri-
catal slices, a small 5-HT component could be seen at
tlater times in the evoked signal (n = 7). When L-trypto-
aphan (a 5-HT precursor) was injected with fluoxetine to
(
further increase extracellular 5-HT, the 5-HT component (
of the evoked release was increased further (n = 8, Fig- f
ture 7B). Addition of GBR12909 to the treatment regi-
(men reduced the 5-HT signal (n = 7, Figure 7B). Overall,
Sthe results suggest that 5-HT collects slowly in the DA
(terminals and that ongoing fluoxetine treatment is nec-
t
essary to maintain a small 5-HT component in the DA- f
containing vesicles of the dorsal striatum. w
fIn slices cut to contain the nucleus accumbens (NAc)
tshell, we did not see significant corelease of 5-HT with
cDA after fluoxetine injections. Therefore, to boost the
vlevel of endogenous 5-HT, one group of mice was in-
c
jected with L-tryptophan and clorgyline (a monoamine i
oxidase inhibitor) together with fluoxetine (see Experi- (
pmental Procedures). After at least 8 days of this treat-
tment, a small 5-HT component could be detected (Fig-
ture 7C). DA was still the overwhelmingly dominant
tcomponent in the electrically stimulated signal. Addi-
e
tion of GBR12909 to the treatment of L-tryptophan, G
clorgyline, and fluoxetine significantly reduced the t
l5-HT component in a second group of mice (Figure 7D).
wFor comparison, a voltammogram is shown at t2 from
ma drug-free mouse (bottom, left, Figure 7D).
dIn both the dorsal striatum and the NAc shell, the
c
5-HT component was small and highly contaminated
by the DA signal. Therefore, we did not attempt to esti-
mate the concentration of the 5-HT signal beyond sim- a
%ple detection and identification. The shape of the volt-
ammograms were appropriate and similar to the ones e
Nobtained after in vitro incubation of striatal slices with
10–20 nM exogenous 5-HT for 2 hr. For DA standards tigure 7. Vesicular Corelease of DA and 5-HT after Chronic In Vivo
reatments to Elevate Extracellular 5-HT
A) A voltammogram at 3 s after the peak of a large signal obtained
rom a dorsal-striatum brain slice cut after injecting a mouse for 21
ays with fluoxetine (Fluox) and L-tryptophan (Trp). The arrow (O
abel) near 550 mV represents the amplitude of the oxidation peak
urrent, and the arrow (R label) near −30 mV represents the ampli-
ude of the reduction current. The reduction current near −30 mV
rises mainly from 5-HT.
B) The ratio of the reduction current to the oxidation peak current
R/O ratio) in the dorsal striatum for mice injected with the following
or R21 days: saline as a control (Cont), fluoxetine (Fluox), fluoxe-
ine + L-tryptophan (Trp), or fluoxetine + L-tryptophan + GBR12909
* indicates significantly different from the control with p < 0.05).
tandard error bars are shown.
C) An example of an electrically stimulated release measured in
he NAc from a slice cut after treating a mouse for 14 days with
luoxetine, L-tryptophan, and clorgyline (Clorg). The signal is over-
helmingly caused by DA, as indicated by the DA voltammogram
rom the signal peak (t1). However, after the DA signal has substan-
ially decayed, 4 s after the peak (t2), a small 5-HT component is
learly present, as revealed by the characteristic mixed DA/5-HT
oltammogram with broad reduction peak. The arrowhead indi-
ates −30 mV where the 5-HT reduction current was measured, but
t is likely contaminated by DA.
D) In another group of mice, the injections of fluoxetine, L-trypto-
han, and clorgyline also contained GBR12909 to inhibit DATs. This
reatment significantly reduced the 5-HT component compared to
he non-GBR12909 treatment, as indicated by the smaller reduc-
ion current at −30 mV in the t2 voltammogram (arrow head). The
voked signal decays relatively slowly, probably due to residual
BR12909. In all of these cases, the small 5-HT component is con-
aminated by the larger DA component. The voltammogram on the
eft shows a pure DA voltammogram at t2 from a drug-free mouse
here the reduction current at −30 mV (arrow) is virtually 0. Voltam-
ograms are averages of 5 to 30 individual voltammograms to re-
uce noise. The voltammogram labeled as t2 in drug-free shows a
ommon voltammogram seen in drug-free striatal slices.nd under drug-free conditions, the R/O ratio is always
0.15. The increased R/O ratios for the dorsal striatum
xperiments are given in Figure 7B. The R/O ratio in the
Ac shell was 0.38 ± 0.04 (n = 12) during fluoxetine,
ryptophan, and clorgyline treatment, and the ratio de-
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71creased to 0.25 ± 0.03 (n = 11) when GBR12909 was
also present (p < 0.01). GBR12909 was without signifi-
cant effect when fluoxetine was left out of the treatment
regimen. Overall, these results suggest the following:
after blocking 5-HT transporters and elevating endoge-
nous 5-HT, there is a small component of 5-HT core-
lease with DA only when DATs are active.
Discussion
In the striatum, the extremely dense DA fibers and DATs
are located close to the sparser 5-HT terminals
(Björklund and Lindvall, 1984; Coulter et al., 1996; Zhou
et al., 2001). Because DATs have a low affinity for 5-HT
(Giros et al., 1991; Pristupa et al., 1994; Shaskan and
Snyder, 1970; Eshleman et al., 1999), they normally
have little opportunity to bind 5-HT, which is efficiently
recycled into serotonergic terminals by 5-HT transpor-
ters. When SSRIs block 5-HT transporters, extracellular
5-HT is elevated (Figure 8). It remains in the extracellu-
lar space longer and diffuses farther. Under those con-
ditions, our results indicate that the striatal DATs are
able to transport significant amounts of 5-HT into DA
terminals. As suggested by our results with mice (Fig-
ure 6), this process likely proceeds slowly during SSRI
treatment of patients, possibly contributing to the many
days of SSRI treatment required before achieving anxi-
olytic benefits (Baldessarini, 2001; Nemeroff and Ow-Figure 8. Schematic Representation of the Hypothesized DAT-
Dependent 5-HT Accumulation in Striatal DA Terminals after
Chronic SSRIs
(Left) Under normal conditions, when the 5-HT transporters (seroto-
nin transporters, SERT) are functional, the released 5-HT is effi-
ciently taken back into 5-HT terminals. Consequently, the extracel-
lular 5-HT concentration remains low. DATs on DA terminals have
little chance to uptake 5-HT. (Right) DATs may uptake a portion of
endogenously released 5-HT into DA terminals when the extracellu-
lar 5-HT concentration is elevated after the SERTs are inhibited by
SSRIs. Once inside the DA terminals, 5-HT is further sequestered
into DA terminals through the vesicular monoamine transporter
(VMAT), which has similar affinity for DA and 5-HT. Subsequently,
5-HT partially displaces DA from DA vesicles, and the two neuro-
transmitters are coreleased.ens, 2002). Once inside the DA terminals, 5-HT is se-
questered into DA vesicles through the vesicular
monoamine transporter, which has similar affinities for
DA and 5-HT (Yelin and Schuldiner, 2002). Our results
are consistent with evidence suggesting that 5-HT may
accumulate into DA cell bodies after genetically delet-
ing an enzyme for 5-HT degradation or deleting the
5-HT transporters or after loading DA cells with 5-HT
precursors (Cases et al., 1998; Jackson and Wightman,
1995; Zhou et al., 2002).
Despite the internal consistency of our results, other
events could contribute to the effects we observed.
During SSRI treatment, the richer innervation of the
midbrain DA areas by serotonergic fibers could have
altered the overall 5-HT and DA metabolism, and that
could have contributed in a complex manner to the ele-
vated 5-HT and decline in DA that we saw. Another po-
tential problem is that systemic injection of fluoxetine
may affect the activity of 5-HT neurons, which in turn
may affect 5-HT synthesis and content. We indeed saw
a small decline in striatal 5-HT content after fluoxetine
treatment, which might have been caused by de-
creased 5-HT synthesis, but we have attributed that fall
mainly to the decreased reuptake of 5-HT after 5-HT
transporter inhibition.
When patients take fluoxetine (Prozac) and inhibit
5-HT reuptake into 5-HT terminals, our evidence sug-
gests that there is a DAT-dependent uptake of 5-HT into
DA terminals of the striatum. A DAT-dependent 5-HT
signal was detected using HPLC (Figure 6), owing to its
extremely high sensitivity. The vesicular release of this
5-HT could only be detected by voltammetry under
specific experimental circumstances owing to the rela-
tively low sensitivity of fast cyclic voltammetry, which
can only detect signals that reach about 10–20 nM at
the carbon fiber. Under particular conditions (Figure 7),
the small 5-HT signal arising from vesicular release
could be detected in the dorsal striatum after fluoxetine
treatment. In the NAc shell, however, it was necessary
to further boost the in vivo 5-HT concentration caused
by fluoxetine by decreasing breakdown with a mono-
amine oxidase inhibitor (clorgyline) in combination with
a 5-HT precursor (L-tryptophan). This difference be-
tween the dorsal striatum and NAc shell may have
arisen from the greater density of DATs in the dorsal
striatum, where 5-HT was more efficiently taken into DA
terminals after fluoxetine treatment. These results sug-
gest that the dense DA terminals and the highly ex-
pressed DATs may participate in 5-HT homeostasis and
signaling in the striatum, a brain area important for re-
ward and emotion as well as for motion control (Berke
and Hyman, 2000; McClure et al., 2003; Schultz et al.,
2003).
Functional Importance of DA and 5-HT Corelease
SSRIs, which block 5-HT reuptake, are among the most
effective and prescribed antidepressant therapies, indi-
cating the importance of serotonergic systems in the
pathophysiology of depression (Baldessarini, 2001; Nem-
eroff and Owens, 2002; Delgado, 2000; Wong et al.,
1995). Animal models and clinical findings also have
implicated the mesoforebrain DA system in depression
(D’Aquila et al. 2000; Zangen et al. 2001; Willner 2002).
Neuron
72For example, the striatal DA concentration and the den- H
sity of striatal DATs were found to be abnormal in pa- v
tients with major depressive disorder (Laasonen-Balk t
et al., 1999; Meyer et al. 2001). Our results suggest that
EDATs may influence 5-HT signaling, providing a basis
for SSRI-induced interaction between these neuro-
Mtransmitter systems. Our conclusion is also consistent W
with a study employing microdialysis that showed d
GBR12909 increased extracellular 5-HT in the striatum r
zof 5-HT transporter knockout mice. The increased ex-
ttracellular 5-HT may have arisen from GBR12909 inhibi-
mtion of DAT-mediated 5-HT uptake (Shen et al., 2004).
1Our results further indicate that there is DA and 5-HT
cotransmission in cases where extracellular 5-HT is s
sufficiently elevated. t
Ectopic 5-HT plays vital roles in neuronal develop- 5
ament (Gaspar et al. 2003). Blockade of 5-HT transpor-
Iters with fluoxetine during early postnatal life induces
odepressive symptoms in adulthood (Ansorge et al.
t
2004). It is possible that during this chronic fluoxetine 5
treatment a certain amount of 5-HT goes into DA ter- o
minals (particularly in the striatum) and contributes to I
dthe 5-HT signaling that is responsible for the behavioral
sabnormalities. In mature animals, we hypothesize that
athe ectopic storage of 5-HT into DA terminals and the
aconsequent corelease of DA and 5-HT produce a num-
b
ber of consequences. The competition between DA and s
5-HT for the DAT, for the vesicular monoamine trans- t
porter, and for the intravesicular space slightly reduces e
DA signaling, as indicated in Figure 1D. This
I5-HT/DA competition at DA terminals also may occur
Iduring the potentially life-threatening serotonin syn-
mdrome. In this syndrome, elevated 5-HT activity is
d
caused by dietary 5-HT precursor overloading or by the s
combined use of SSRIs and monoamine oxidase inhibi- w
2tors (Sternbach, 1991). These abnormal situations
awould favor DAT uptake of 5-HT. DAT uptake of 5-HT
eand consequent corelease alters the timing, location,
ointensity, and interaction of 5-HT and DA signaling.
0
The striatum expresses a plethora of 5-HT receptors r
coupled to diverse signaling pathways (Barnes and a
Sharp, 1999; McMahon et al., 2001). The striatum also a
Fexpresses multiple types of DA receptors that are cru-
dcial for the activity of the basal ganglia (Missale et al.,
t1998; Greengard, 2001). The relationship between DA
mand 5-HT signaling is likely vital for normal behavior and
f
for the pathology that can be treated with SSRIs. The
striatum, the ventral striatum in particular, is critically I
involved in the neuronal processes of reward and emo- D
tional functions (Berke and Hyman, 2000; McClure et m
Aal., 2003; Schultz et al., 2003). Thus, the enhanced
eparticipation of the striatal DA system in 5-HT signaling
iduring chronic SSRI treatment may contribute to the
G
therapeutic efficacy of SSRIs. a
Our results do not connect the change in the relation- m
ship between DA and 5-HT signaling to a behavioral t
output. Recent evidence indicates that antidepressant d
etreatment induces neurogenesis that is prerequisite for
anxiolytic action (Santarelli et al., 2003). We can con-
7clude, however, that the extremely dense DATs in the
i
striatum are able to transport 5-HT into DA terminals t
when extracellular 5-HT is elevated. Normally, this pro- f
cess may be of little significance because of its low m
sefficiency and the low extracellular 5-HT concentration.owever, it may play a functional role when 5-HT is ele-
ated for prolonged times during treatment with SSRI-
ype antidepressants.
xperimental Procedures
ice, Striatal Brain Slices, and Voltammetry
ild-type C57BL/6J mice were used at 3–6 months of age. Under
eep anesthesia, mice were decapitated, and the brains were
apidly removed following the methods of Zhou et al. (2001). Hori-
ontal striatal slices (400 m) were cut on a vibratome, held at room
emperature, and studied at 30°C in 125 mM NaCl, 2.5 mM KCl, 1.3
M MgCl2, 2.5 mM CaCl2, 1.25 mM Na2HPO3, 25 mM NaHCO3, and
0 mM glucose saturated with 95% O2 and 5% CO2.
Homemade carbon-fiber microelectrodes were used for fast-
can cyclic voltammetry. The microelectrodes were calibrated after
he experiment using fresh standards: 0.5–5 M DA, 0.2–2 M
-HT, and mixtures of 0.5–2 M DA and 0.01–1 M 5-HT (Zhou et
l., 2001). An Axopatch 200B amplifier and pClamp software (Axon
nstruments) were used to acquire and analyze the data. Scans (10
r 20 Hz) of the microelectrode potential were from 0 mV to −400
o 1000 to −400 to 0 at a rate of 300 mV/ms and were sampled at
0 kHz. The net current due to the electrochemical reaction was
btained by digital subtraction of the ohmic background currents.
ntrastriatal stimuli (1–4 V in amplitude and 1 ms in duration) were
elivered using 0.5 M bipolar tungsten electrodes. Recording and
timulation were made in the dorsolateral striatum and the core
nd shell of the nucleus accumbens. Because the dorsolateral stri-
tum has denser DA terminals and DATs than the nucleus accum-
ens (Coulter et al., 1996; Descarries and Mechawar, 2000), its DA
ignal is generally larger in amplitude and faster in decay. Despite
hese differences in the signal, the overall conclusions were gen-
rally the same in these two regions of the striatum.
mmunostaining
mmunohistochemistry was performed according to published
ethods (Pickel and Chan, 1999; Zhou et al., 2001). Tyrosine hy-
roxylase (TH) and 5-HT staining were conducted with control
lices, slices incubated in 2 M 5-HT for 2 hr, or slices pretreated
ith 1 M GBR12909 for 1 hr followed by 2 hr incubation with
M 5-HT and 1 M GBR12909. Fluoxetine and nisoxetine (each
t 1 M) were present under all conditions to block 5-HT and nor-
pinephrine transporters, respectively. Afterward, slices were thor-
ughly washed. The slices were fixed in 4% paraformaldehyde in
.1 M phosphate-buffered saline (PBS) for 6 hr at 4°C and then
insed thoroughly in PBS. Sections of 25 m were cut on a cryostat
nd incubated overnight with goat anti-5-HT antibody and rabbit
nti-TH antibody. They were then reacted with a mixture of Alexa
luor 488-conjugated donkey anti-rabbit IgG and Cy3-conjugated
onkey anti-goat IgG antisera. Microscopic observations and digi-
al microphotography were made on a Bio-Rad MRC1024 confocal
icroscope using LaserSharp 2000 software. Digital images were
urther processed using NIH ImageJ and Adobe Photoshop.
n Vivo Drug Administration to Mice
rugs were dissolved in 0.2 m filtered saline and administered to
ale mice (3–6 months of age) intraperitoneally once a day (at 10
M) for up to 18 days for the data displayed in Figure 6 (Bymaster
t al., 2002). The mice were divided into four groups, each receiving
njections of saline or fluoxetine (10 mg/kg body weight) or
BR12909 (5 mg/kg body weight) or a mix of fluoxetine (10 mg/kg)
nd GBR12909 (5 mg/kg). To obtain striatal tissue samples, the
ice were sacrificed 4 hr after the last drug injection. For each of
he four groups, three to six mice were sacrificed on each chosen
ay of the time course, and four striatal samples were taken from
ach mouse for HPLC analysis.
For voltammetry detection of 5-HT in the dorsal striatum (Figures
A and 7B), mice were divided into five groups, each receiving one
njection a day: saline, fluoxetine (10 mg/kg body weight), fluoxe-
ine (10 mg/kg) + L-tryptophan (50 mg/kg), GBR12909 (5 mg/kg), or
luoxetine (10 mg/kg) + L-tryptophan (50 mg/kg) + GBR12909 (5
g/kg). At least three mice from each group were sacrificed, and
triatal brain slices were cut on the 7th, 14th, or 21st day of treat-
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73ment. To significantly detect the 5-HT component, the injections
had to continue for many days, with the last injection coming only
2 hr before the slices were cut. The 5-HT component was largest
within the first hour after cutting the slice. We reasoned that the
released synaptic vesicles initially contain DA and 5-HT, but as time
passed vesicles that were released were refilled only with DA be-
cause the SSRI was no longer present and the 5-HT was no longer
elevated in those slices.
A slightly different protocol was used to increase the extracellular
5-HT concentration for voltammetric detection in the NAc shell
(Figures 7C and 7D). One group of mice was treated twice a day
with L-tryptophan (100 mg/kg), clorgyline (1 mg/kg), and fluoxetine
(7.5 mg/kg). A second group of mice was treated twice a day with
GBR12909 (4 mg/kg) as well as L-tryptophan, clorgyline, and fluox-
etine. A third group of mice was treated with L-tryptophan, clorgy-
line, and GBR12909 but no fluoxetine. A saline group was used as
the control. Two mice from each group were sacrificed, and striatal
brain slices were cut on the 4th, 8th, 12th, and 16th day of treat-
ment. A small 5-HT component was only detected beyond 8 days
of injections.
HPLC Analysis for DA and 5-HT
DA and 5-HT content in dorsolateral striatal brain samples was de-
termined by challenging with 200 mM KCl followed by several
rounds of physical disruption by trituration. The disrupted slices
were then freeze-thawed, sonicated, and filtered at 0.2 m. DA and
5-HT contents were analyzed using an HPLC-EC system (ESA,
Chelmsford, MA) (Yuan et al., 2002; Pidoplichko et al., 2004). On
the HPLC chromatograms, DA and 5-HT were separate peaks that
were quantified by comparing their heights to those of fresh DA
and 5-HT standard curves using linear regression analysis. DOPAC
arising from the metabolic breakdown of DA was also detected by
HPLC and compared to DOPAC standards.
Statistics
Descriptive statistics were performed using OriginLab (OriginLab
Corporation, Northampton, MA) or StatMost (Dataxiom Software
Inc., Los Angeles, CA). Comparisons of the distributions of DA and
5-HT contents from individual samples were made using Kolmo-
gorov-Smirnov (K-S) test with StatMost, and p values %0.05 were
considered statistically significant.
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